Immunization of syngeneic BMT recipients with either AML-lysate–pulsed DCs or irradiated AML cellular vaccines results in a significant decrease in leukemia-related mortality.
B6 recipients were lethally irradiated on day −1 and infused with syngeneic B6 BM on day 0. Cohorts of recipients (n = 10 per group) received either no manipulation (BMT/AML control) or 3 weekly doses of tumor-pulsed or nonpulsed DCs (days 59, 66, and 72) or irradiated AML vaccines (107 per dose) given subcutaneously (days 66 and 73). Mice were challenged with a lethal dose of C1498 cells (105) on day 80 post-BMT. A separate group of mice received syngeneic BMT but were not challenged with C1498 cells. A Kaplan-Meier survival plot shows days post-BMT listed on the x-axis and the proportion surviving on the y-axis. The actuarial survival rate of recipients of tumor-pulsed DCs or irradiated AML cellular vaccines was significantly higher (P < .006) than control animals receiving BMT only or recipients receiving unpulsed DCs.
